ReviewHelicobacter2020
Previous Helicobacter pylori infection-induced atrophic gastritis: A distinct disease entity in an understudied population without a history of eradication.
Review in Helicobacter, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Impact ofFrontiers in microbiology · 2025Pooled it
- The Association betweenGenes · 2020Trial
- Sensitivity and specificity of endoscopic and radiographic screening for localized gastric cancer in a real-world, population-based setting.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Clinical feasibility of deep learning-assisted classification of Helicobacter pylori infection in endoscopic imagery: a reader study.The Korean journal of internal medicine · 2026Article
- Oleuropein derived from olive leaves inhibits the activity ofRSC advances · 2026Article
- Rapid diagnosis ofFrontiers in public health · 2026Article
- Comparison of clinicopathological features of gastric carcinoma in autoimmune gastritis with and without Helicobacter pylori infection.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Article
- Recent advancement in endoscopic diagnosis for risk stratification of gastric cancer.Clinical endoscopy · 2025Review
- Identification of Oxidative Stress-Related Markers for Chronic Atrophic Gastritis Using WGCNA and Machine Learning.Digestive diseases and sciences · 2025Article
- Article
- Gyrus-like endoscopic changes in autoimmune gastritis with pastWorld journal of gastrointestinal endoscopy · 2025Article
- Gastric cancer risk after Helicobacter pylori eradication in gastritis and peptic ulcer: a retrospective cohort study in Japan.BMC gastroenterology · 2025Article
- Gastric cancer in patients withWorld journal of gastrointestinal oncology · 2025Article
- Relationship between gastric mucosal atrophy, cystic dilatation, and histopathological characteristics.BMC gastroenterology · 2025Article
- Characteristics of Early Gastric Cancer in a Patient with a History of Helicobacter pylori Infection and No History of Eradication Therapy.Internal medicine (Tokyo, Japan) · 2025Article
- Development and validation of a clinical model to predict low-grade intraepithelial neoplasia in chronic atrophic gastritis patients: a retrospective observational multicenter analysis.Frontiers in oncology · 2025Article
- Research progress on the relationship betweenFrontiers in microbiology · 2025Review
- Exploring the Antibacterial Activity ofTropical life sciences research · 2024Article
- Factors Predicting Effectiveness of Eradication Therapy forLife (Basel, Switzerland) · 2024Article
- Clinical Characteristics of Patients With Previous Helicobacter pylori Infection-Induced Atrophic Gastritis.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individuals with chronic atrophic gastritis who are negative for active H. pylori infection with no history of eradication therapy have been identified in clinical practice. By excluding false-negative and autoimmune gastritis cases, it can be surmised that most of these patients have experienced unintentional eradication of H. pylori after antibiotic treatment for other infectious disease, unreported successful eradication, or H. pylori that spontaneously disappeared. These patients are considered to have previous H. pylori infection-induced atrophic gastritis. In this work, we define these cases based on the following criteria: absence of previous H. pylori eradication; atrophic changes on endoscopy or histologic confirmation of glandular atrophy; negative for a current H. pylori infection diagnosed in the absence of proton-pump inhibitors or antibiotics; and absence of localized corpus atrophy, positivity for autoantibodies, or characteristic histologic findings suggestive of autoimmune gastritis. The risk of developing gastric cancer depends on the atrophic grade. The reported rate of developing gastric cancer is 0.31%-0.62% per year for successfully eradicated severely atrophic cases (pathophysiologically equal to unintentionally eradicated cases and unreported eradicated cases), and 0.53%-0.87% per year for spontaneously resolved cases due to severe atrophy. Therefore, for previous H. pylori infection-induced atrophic gastritis cases, we recommend endoscopic surveillance every 3 years for high-risk patients, including those with endoscopically severe atrophy or intestinal metaplasia. Because of the difficulty involved in the endoscopic diagnosis of gastric cancer in cases of previous infection, appropriate monitoring of the high-risk subgroup of this understudied population is especially important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.